27 results
8-K
EX-99.1
1z23t1iu
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
htbtgnwaglz74xnrghb
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
543le
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
56a603qrpvm7vtnsp8bl
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm